PEPTIDE COMPARISON

CJC-1295 vs Ipamorelin

Early endocrine research compared without treating biomarker changes as outcomes.

QUICK ANSWER

CJC-1295 vs Ipamorelin: the main difference.

Both can affect the growth-hormone axis through different mechanisms. The available evidence is much stronger for short-term biomarker effects than for durable benefits or long-term safety.

Decision field	CJC-1295	Ipamorelin
Human research	Small hormone-response studies	Early pharmacology and limited clinical studies
Primary research	Long-acting GHRH signaling	Ghrelin-receptor signaling
FDA status	Not approved	Not approved
Mechanism	GHRH analog	Growth-hormone secretagogue
Evidence confidence	Low for clinical outcomes	Low for clinical outcomes

SOURCES

CJC-1295 vs Ipamorelin sources.

Human trial / 2006Prolonged stimulation of growth hormone and IGF-1 by CJC-1295PubMed WADA / 20262026 Prohibited ListWorld Anti-Doping Agency FDA / 2024–2026FDA briefing and compounding safety concerns for ipamorelinU.S. FDA

CJC-1295 vs Ipamorelin: the main difference.

CJC-1295 vs Ipamorelin sources.

Questions related to CJC-1295 vs Ipamorelin.

Compare the next decision.